Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lymphatic filariasis (LF)
- Living with filariasis
- Lymphatic filariasis - global burden
- Regional overview
- Lymphatic filariasis - some facts
- Context
- LF is a disease of stigma and poverty
- Basic biology of the parasite
- Animated life cycle
- Life cycle of Wuchereria bancrofti
- Mosquito vector genera (1)
- Mosquito vector genera (2)
- Global distribution of major LF vectors
- Periodicity
- Transmission
- Microfilaria
- Diagnosis of infection
- Diagnosis of infection - ICT cards
- Clinical pathology
- Filaria dance sign
- Lymphatic filariasis (elephantiasis)
- Global programme to eliminate LF
- Basis of strategy
- Albendazole, Ivermectin and DEC
- LF endemic countries and territories, 2006
- Elimination strategy
- Global alliance for the elimination of LF
- Need to map disease distribution
- ICT cards
- LF distribution in Africa - prevalence map
- Programme success
- Programme progress
- Programme in action
- Percent decline in mf prevalence and mf load
- Reduction in mf prevalence after 2-3 MDAs
- Impact of MDA on lymphatic filariasis
- Decline in density of the parasite and % mf
- Compliance
- The Zanzibar story (1)
- The Zanzibar story (2)
- Home based care management for LF patients
- Prevalence of CFA and mf post MDA
- Mf prevalence and density recorded at Kwahani
- Mf prevalence and density recorded at Kizimkazi
- Vectors infection and infectivity rates 2001-2004
- Vectors annual transmission potential , Mali
- Elimination of LF in Nigeria
- Impact of MDA on filarial DNA rates
- Lymphatic filariasis - the numbers (2000-2007)
- GPELF by the numbers
- GPELF by the numbers (children)
- GPELF by the numbers (women)
- Drug donations (2000-2007)
- Drugs purchased (2000-2007)
- From drug donations to development partnership
- LF endemic villages near Cairo, Egypt
- Egypt results
- The path to elimination - the need evaluate
- Decisions need to be made
- Currently recommended diagnostics
- LF drugs effectiveness as anti-parasitic drugs
- Impact of MDAs on helminths and scabies
- Collateral benefits
- The stigma from LF in Sri Lanka
- LF in Sri Lankan women
- LF in Sri Lankan men
- LF in Sri Lanka
- Bednets as additional prevention of LF
- Bednets
- Bednet use reduces W, bancrofti transmission
- Unique features of LF programme
- Pro-poor and pro-active preventative chemo (1)
- Pro-poor and pro-active preventative chemo (2)
- A cost effective intervention
- Key challenges
- We know it works
- Costs per person per year NTD chemotherapy
- Thank you
Topics Covered
- Lymphatic Filariasis as a disabling, mosquito-borne parasitic disease
- Control strategies through annual drug therapy
- Control of vector mosquitoes
- The progress in the Global Programme; mapping, monitoring, evaluation, pathology, morbidity management
- Multiple benefits of drugs in other conditions
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Molyneux, CMG, D. (2010, November 22). Lymphatic filariasis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/YMSC4095.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Molyneux’s research has been supported by the UK Department for International Development, the World Health Organization, the Bill and Melinda Gates Foundation, GlaxoSmithKline, Sanofi, and Sightsavers International who have provided support for work on Neglected Tropical Disease at the Liverpool School of Tropical Medicine. He also receives Honoraria from The Royal Society of Tropical Medicine and Hygiene, and Sightsavers.
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
This talk is
about the diseases associated
with lymphatic filariasis, a
parasitic infection transmitted
by mosquitoes.
My name is Professor David Molyneux,
from the Center for Neglected
Tropical Diseases at the Liverpool
School of Tropical Medicine.
0:19
Lymphatic filariasis
has been described
as a potentially eradicable disease.
The international task force
identified six diseases in 1993
which could be eradicated
from Planet Earth.
That means that no longer,
any of these organisms
would be on the planet.
Lymphatic filariasis was
amongst those infections.
The World Health Assembly, in 1997,
passed a resolution which called
for the elimination of
lymphatic filariasis
as a public health problem.
The first series of
slides in this lecture
demonstrate the public health
problem experienced by millions
of people who are infected
by this condition.
1:04
All these slides were
taken in the field,
and the quotes are
from the patients who
are suffering from these infections.
As you will see, they cause
significant disability.
They stigmatize people.
They reduce their capacity to work.
And they have a significant impact
on the productivity of populations
across the endemic
areas of the globe.